The diabetes drug Onglyza is under the FDA’s microscope as the agency said it would review possible heart risks associated with the medication.
The decision comes after a study published in the New England Journal of Medicine. The study flagged an increase in heart failure hospitalizations among patients who used Onglyza (saxagliptin). The active ingredient is also part of a metformin combination drug, Kombiglyze.
The analysis of the saxagliptin clinical trial data is part of a broader evaluation of all type 2 diabetes drug therapies and cardiovascular risk, stated the FDA.